Definitive Healthcare (DH)
(Delayed Data from NSDQ)
$5.62 USD
-0.03 (-0.53%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $5.61 -0.01 (-0.18%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth F Momentum B VGM
Price, Consensus and EPS Surprise
DH 5.62 -0.03(-0.53%)
Will DH be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for DH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DH
DH or PRVA: Which Is the Better Value Stock Right Now?
Bears are Losing Control Over Definitive Healthcare (DH), Here's Why It's a 'Buy' Now
DH: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Medical Info Systems Stocks to Buy for Stable Returns
Definitive Healthcare Corp. (DH) Matches Q1 Earnings Estimates
Definitive Healthcare Corp. (DH) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Other News for DH
ClearBridge Small Cap Growth Strategy Q2 2024 Commentary
Definitive Healthcare launches redesigned mobile app to enhance access to healthcare commercial intelligence
Definitive Healthcare Corp. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Definitive Healthcare: Weak Near-Term Growth To Put Valuation In Rangebound
Small-cap, buy-rated stocks with positive estimate revision factors - BofA